Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Anti-infective
26%
Biologically Equivalent Dose
17%
Cancer Patients
17%
Chemotherapy
43%
Cisplatin-ineligible
17%
Clinical Oncology
35%
Combination Therapy
24%
Comorbidity
21%
Confidence Interval
73%
Head-and-neck Cancer
35%
Head-and-neck Squamous Cell Carcinoma (HNSCC)
22%
Immune Checkpoint Inhibitor Therapy
32%
Immune Checkpoint Inhibitors
60%
Impact on Patients
17%
In Situ
17%
Infected Patients
34%
Infection Rate
18%
Infection Risk
42%
Intensive Care Unit Admission
21%
Ipilimumab
22%
Kaplan-Meier
17%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
35%
Median Overall Survival
29%
Metastatic Non-small Cell Lung Cancer
20%
Metformin
17%
Multivariable
40%
National Cancer Database
31%
Neoadjuvant
21%
Nivolumab
35%
Non-small Cell Lung Cancer (NSCLC)
41%
Odds Ratio
31%
Overall Survival
83%
Patient Demographics
17%
Pembrolizumab
100%
Phase II Study
17%
Phase II Trial
22%
Preoperative Chemotherapy
17%
Prognostic Impact
17%
Progression-free Survival
28%
Radical Resection
17%
Radiosensitization
17%
Real-world Experience
17%
Renal Cancer
17%
Single Port
17%
Stereotactic Body Radiation Therapy
35%
Stereotactic Body Radiotherapy
21%
Survival Outcomes
19%
Upper Tract Urothelial Carcinoma
26%
Urothelial Carcinoma
17%
Young Investigators
35%
Medicine and Dentistry
Adjuvant Radiotherapy
17%
Bladder
23%
Brain Metastasis
17%
Cervical Lymph Node
17%
Cisplatin
17%
Clear Cell Renal Cell Carcinoma
35%
Clinical Oncology
35%
Clinical Trial
19%
Combination Therapy
22%
Connective Tissue Cancer
17%
Diseases
22%
Dyspnea
17%
Earache
17%
Emergency Department
17%
Equivalent Dose
17%
Glycon
17%
Head and Neck Cancer
35%
Head and Neck Squamous Cell Carcinoma
18%
Immune Checkpoint Inhibitor
63%
Immunotherapy
37%
Infection
87%
Intensive Care Unit
17%
Kidney Cancer
17%
Malignant Neoplasm
29%
Muscle Invasive Bladder Cancer
17%
Neoplasm
25%
Nivolumab
20%
Non Small Cell Lung Cancer
52%
Odynophagia
17%
Oncolytic Virotherapy
17%
Oropharynx
17%
Oropharynx Carcinoma
17%
Overall Survival
77%
Patient Population
17%
Pembrolizumab
78%
Plummer-Vinson Syndrome
17%
Progression Free Survival
23%
Radical Resection
17%
Radiosensitizer
17%
Retroperitoneal Lymph Node Dissection
17%
Robot-Assisted Surgery
17%
Small Cell Lung Cancer
17%
Squamous Cell Carcinoma
17%
Stereotactic Body Radiation Therapy
52%
Targeted Therapy
17%
Tonsil
17%
Transitional Cell Carcinoma
35%
Urothelial Cancer
17%
Wart Virus
17%
Whole Brain Radiotherapy
17%
Pharmacology, Toxicology and Pharmaceutical Science
Axitinib
7%
Cabozantinib
7%
Chemoradiation Therapy
6%
Chemotherapy
28%
Comorbidity
11%
Disease Exacerbation
7%
Diseases
5%
Head and Neck Cancer
35%
Head and Neck Squamous Cell Carcinoma
18%
Immune Checkpoint Inhibitor
63%
Immunotherapy
17%
Infection
87%
Ipilimumab
12%
Kidney Cancer
17%
Kidney Metastasis
6%
Malignant Neoplasm
6%
Metformin
17%
Nivolumab
20%
Non Small Cell Lung Cancer
70%
Oncolytic Virus
17%
Overall Survival
61%
Pembrolizumab
78%
Progression Free Survival
26%
Radiosensitizing Agent
17%
Renal Cell Carcinoma
17%
Retrospective Study
6%
Transitional Cell Carcinoma
17%
Valaciclovir
7%
Virotherapy
17%